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Economics, Lund, Sweden; 7University of Lyon, Lyon, FranceA B S T R A C TObjective: A review of existing economic models in major depressive
disorder (MDD) highlighted the need for models with longer time
horizons that also account for heterogeneity in treatment pathways
between patients. A core discrete event simulation model was devel-
oped to estimate health and cost outcomes associated with alternative
treatment strategies.Methods: This model simulated short- and long-
term clinical events (partial response, remission, relapse, recovery, and
recurrence), adverse events, and treatment changes (titration, switch,
addition, and discontinuation) over up to 5 years. Several treatment
pathways were deﬁned on the basis of ﬁctitious antidepressants with
three levels of efﬁcacy, tolerability, and price (low, medium, and high)
from ﬁrst line to third line. The model was populated with input data
from the literature for the UK setting. Model outputs include time in
different health states, quality-adjusted life-years (QALYs), and costs
from National Health Service and societal perspectives. The codes are
open source. Results: Predicted costs and QALYs from this model aresee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.11.012
tiv-ceutical.com.
ndence to: Anne-Lise Vataire, Health Economics and
, France.within the range of results from previous economic evaluations. The
largest cost components from the payer perspective were physician
visits and hospitalizations. Key parameters driving the predicted costs
and QALYs were utility values, effectiveness, and frequency of physi-
cian visits. Differences in QALYs and costs between two strategies with
different effectiveness increased approximately twofold when the
time horizon increased from 1 to 5 years. Conclusion: The discrete
event simulation model can provide a more comprehensive evaluation
of different therapeutic options in MDD, compared with existing
Markov models, and can be used to compare a wide range of health
care technologies in various groups of patients with MDD.
Keywords: antidepressants, cost-effectiveness, depression, discrete
event simulation.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Major depressive disorder (MDD) is a complex public health problem
associated with signiﬁcant medical, social, and economic burden.
The lifetime prevalence of MDD ranges from 10% to 15% [1]. The
disease remains highly recurrent despite therapeutic progress [2].
Both unipolar and bipolar depression are associated with an
increased risk of suicide, which is overall about 20 times higher
than in the general population [3]. In 2004, the total costs of MDD
reached €118 billion in Europe, with 25% outpatient care and drug
costs, 8% hospitalization costs, and 64% indirect costs resulting from
lost productivity and mortality [4]. MDD is predicted to become the
second leading contributor to the global disease burden by 2020 [5].
There are a large number of antidepressant drugs on the
market, for instance, 27 in the British National Formulary, withdifferent efﬁcacy and tolerability proﬁles, as well as different
costs. In this context, a cost-effectiveness model would be useful
to inform the choice between alternative treatment strategies.
Decision tree (DT) models have been applied to assess the cost-
effectiveness of MDD treatments. They have the main limitation
of being inﬂexible when covering the disease’s long-term events
[6]. Events such as recurrence and its corresponding health states
are missed by DT models because the model time horizon covers
only the acute phase of depression, although treatment contin-
ues after remission to prevent relapse and recurrence. Represent-
ing these missed events is technically possible within the DT
models. This would, however, result in broadening the number of
corresponding health states. The use of a Markov model is
another alternative. Simple Markov models, however, lack mem-
ory [7] because they neither consider previous depressiveociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Outcomes Research, Creativ-Ceutical, 215 rue du Faubourg Saint-
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history would necessitate broadening the number of health
states, which, as in DT models, may impede model implementa-
tion and analysis, or using patient-level simulation [6].
The discrete event simulation (DES) approach overcomes
these limitations of DT models or simple Markov models and is
more ﬂexible and less computing intensive than Markov models
running at the patient level [8]. DES models conceptualize the
course of patients in terms of experienced events and their effect
on current and future health, medical resource use, and other
components, continuously in time. Patient characteristics, so-
called attributes, which affect event occurrence, can be updated
accordingly.
This article presents a core DES model, accounting for long-
term clinical events and treatment pathways, to estimate health
and cost outcomes associated with alternative treatments in
different groups of patients with MDD. Analyses were conducted
with ﬁctitious treatment strategies to identify the main drivers of
incremental costs and quality-adjusted life-years (QALYs) between
alternative treatment strategies in MDD, including patient and
treatment characteristics, and to assess the validity of the model.
This is an open-source model, and the code is available at
www.open-model-mdd.org. This approach aims at transparency,
at facilitating the use of the model by researchers from academia,
health technology assessment agencies, or industry, and at
enabling other researchers to contribute to the development of
the model, for example, by sharing enhancements in the pro-
grams or by providing new input data.Methods
After reviewing existing models in MDD, we developed a struc-
ture capturing the main aspects of treatment, related to effective-
ness and tolerability. Three meetings were organized withFig. 1 – Example of treatment strategy (“medium treatmencoauthors and two additional health economic experts to review
successive versions of the model. Contributors came from six
countries (Canada, France, The Netherlands, Spain, Sweden, and
the United Kingdom) and commented on requirements for
adapting the model to their country. The model was then
implemented, taking into consideration the recommendations
made during the ﬁrst two meetings, and a third meeting was
organized to review the model and discuss results of the initial
analyses.
Model Overview
The model simulates the evolution of depression status,
treatment-related adverse events (AEs), and changes in treat-
ment in a cohort of adult patients with a new episode of MDD.
These patients could have been treated for previous episodes
earlier in their life and have subsequently recovered.
Depression is a long-term disease that often requires several
lines of treatment [9,10]. This model predicts health outcomes
and costs associated with alternative treatment strategies. Each
strategy does not correspond to a single treatment option but
consists of four lines of pharmacological treatment, with two
options at each switch, according to the reason for switch: either
lack of efﬁcacy or AEs. Thus, a treatment strategy can be
represented as a tree diagram, as illustrated in Figure 1. The
model has the ﬂexibility of specifying a treatment line as a
speciﬁc drug or as a combination of several treatments.
The time horizon is ﬂexible in the model. Costs can be esti-
mated from societal and payer perspectives, as detailed below.
Attributes
Several attributes are generated randomly for each patient
individually at the beginning: age, sex, number of previous
depression episodes, and working status. The model user can
specify proportions at baseline for these different attributes tot strategy”). AE, adverse event; LoE, lack of efﬁcacy.
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ular setting. Other attributes are updated during the simulation
according to clinical events that occur. These include depression
status, current treatment, treatment line, treatment dose, pres-
ence or absence of long-term AEs, and presence or absence of
residual symptoms after remission, as well as the number of
previous episodes.
Events
Patient pathways are represented in Figure 2. To simplify, several
events (death due to suicide or other causes, suicide attempt,Clinical
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are not represented in the ﬁgure, although they can occur at any
time.Disease-related events
All events identiﬁed in previous models were included in this
model. The model also included a “partial response” event (deﬁned
as a Z25% decrease in severity scale from the beginning of the
episode for analyses reported herein), because in real practice
treatment modiﬁcation (titration, switch, addition) is possible in
case of lack of improvement after 1 month of treatment. In addition,Full
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is symptom remission as deﬁned in a clinical trial, based on the
Montgomery and Asberg Depression Rating Scale (MADRS) score
(MADRS total score r10), and “full remission,” which is a combina-
tion of clinical remission and normal functioning. This is to account
for the fact that functioning may remain impaired for some time
after clinical remission [8] because of residual symptoms. Among
patients in remission, the time to normal functioning is assumed to
be dependent on the presence of residual symptoms and antide-
pressants may differ in the time to resolution of residual symptoms.Fig. 5 – Tornado charts for non–treatment-relative parameters. Q
variation of the difference in QALYs and societal costs when the
the Table 1. The vertical line represents the base case. AssumpAfter 6 months in full remission, the patient is considered to reach a
state of “recovery.” Thus, different categories of depression status in
the model are new depressive episode, partial response, clinical
remission, full remission, and recovery. A new episode is designated
as a relapse if it occurs after response and before recovery, and as a
recurrence if it occurs after recovery; the monthly risk of relapse is
greater than the monthly risk of recurrence.
Residual symptoms extend the time from clinical remission to
full remission. The model allows for an interaction between
treatments and residual symptoms on time to normal
functioning.Adverse events
Compared with the models in the review, the proposed model has
a high level of detail relating to AEs. Rather than combining all AEs
into one type of event, the most frequent types of AEs are
considered (nausea, diarrhea, and sexual dysfunction, for selective
serotonin reuptake inhibitors; headache, insomnia, and others for
other antidepressants) to account for speciﬁc tolerability proﬁles
associated with different classes of antidepressants [11].
Treatment-related AEs are considered as short-term AEs with the
exception of sexual dysfunction, which is considered as a long-
term AE. Short-term AEs occur during the ﬁrst month of treatment
line [12] and do not last beyond treatment discontinuation. For
each short-term AE, a cost increment and a QALY decrement were
applied. Sexual dysfunction is assumed to be a long-term AE
because it was thought less distressful and less impairing when a
patient is acutely depressed. When the patient is getting better (in
clinical remission), however, this AE starts to have an effect on
quality of life during the simulated length of this AE.Treatment Pathway
A treatment modiﬁcation can occur in case of either an AE or lack
of efﬁcacy (no partial response, no clinical remission, or relapse).
In case of an AE, two options were deﬁned: switch or dose
reduction. In case of lack of efﬁcacy, the options considered were
treatment switch, dose increase, and addition of an antipsychotic.
Combinations of antidepressants were not explicitly considered
but can be entered in the model as switches. Patients developing a
new episode after recovery are assumed to be treated with the
same treatment as that to which they responded earlier.
Patients normally discontinue treatment 6 months after
remission, that is, when reaching recovery. Persistence toALYs, quality-adjusted life-years. Each bar represents the
input values are changed according to scenarios speciﬁed in
tions are shown in bold font.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 8 3 – 1 9 5 187treatment, however, is relatively low in reality, and the model
accounts for the fact that patients can discontinue earlier.
Simulation Algorithm
All patients enter the model with a moderate to severe MDD
episode. Several attributes (mentioned above) and the time to
death (due to all-cause mortality) are simulated at the start. The
simulation then follows a recursive process. Times to the occur-
rence of potential new events are simulated after each event,
until the time horizon has been reached or death occurs, which-
ever comes ﬁrst. Patient attributes are updated at each event. For
example, when the patient reaches clinical remission, times to
full remission and to relapse are simulated. If the time to full
remission is shorter than the time to relapse, the next event is
full remission, and new times to events are generated (e.g., time
to recovery). If the time to relapse is shorter than the time to full
remission, the next event is relapse. At remission, the presence
or absence of residual symptoms is simulated on the basis of a
ﬁxed probability and treatment-emergent sexual dysfunction is
simulated on the basis of a probability depending on treatment.
Probabilities of Events
Times to each AE and most MDD-related events (partial response,
clinical remission, full remission, and relapse) were assumed to
be exponentially distributed. This implies that the probability of
these events was the same every day as long as the patient
attributes are unchanged (as in a Markov model). In case of dose
adjustment (reduction or increase) or addition of an antipsy-
chotic, these probabilities were adjusted by applying a multi-
plicative factor on the time to event. The line of treatment was
assumed to have an effect only on response, remission, and full
remission and was also taken into account by means of a
multiplicative factor. The effect of residual symptoms on full
remission was implemented in the same manner. The time to
recurrence was assigned a Weibull distribution, with a scale
parameter dependent on the number of previous depressive
episodes.
Costs
The following types of costs were included in the model,
expressed in 2011 British pounds (GBP): Costs of antidepressant and antipsychotic medication;
 General practitioner visits including regular visits in the acute
phase and additional visits for AEs or lack of efﬁcacy;
 Psychiatrist visits including regular visits and additional
visits;
 Hospitalization for depression;
 Productivity lost related to absenteeism or presenteeism; and
 Suicide and suicide attempts.
Costs can be estimated from two different perspectives. All costs
listed above are included from the societal perspective, while
productivity costs are not considered from the health care payer
perspective. Unit costs of resources may also differ between these
two perspectives and can be deﬁned according to local context.
For most resource categories, the cost is simply obtained as
the product of the amount of resource used per patient and the
corresponding unit cost. For hospitalization, the cost is calculated
as the number of days in hospital multiplied by the daily cost.
The number of inpatient days per month is assumed to be
dependent on depression status [25]. The model allows estima-
tion of the productivity costs due to depression using either the
human capital approach or the friction cost approach. In the
human capital approach, the cost is estimated as the gross dailywage multiplied by the average number of days of absence per
month depending on depression status, and by the number of
months spent in each disease state. For the friction cost
approach, events corresponding to the beginning and end of sick
leave periods are simulated. The cost of a sick leave is then
calculated as the minimum of the sick leave period and the
friction cost period, multiplied by gross wage and elasticity of
production [13].
The cost of presenteeism was calculated as the product of the
number of underproductive days at work, a coefﬁcient of pre-
senteeism, and gross daily wage.
Quality-Adjusted Life-Years
QALYs are obtained by weighting the time spent in each disease
state by a utility dependent on depression status. Utility values
were taken from the study by Sapin et al. [14] based on the
EuroQol ﬁve-dimensional questionnaire health-related quality-of-
life assessment as recommended in the National Institute for
Clinical Excellence methodological guidance [15]. In case of short-
term AEs, a QALY decrement was subtracted from the previously
cumulated number of QALYs. For sexual dysfunction, a QALY loss,
calculated as the product of a ﬁxed disutility by the simulated
duration of sexual dysfunction, was subtracted. Utility values for
AEs were obtained from the study by Sullivan et al. [16].
Analyses
The model was implemented by using Scilab (www.scilab.org), an
open-source mathematical software package. It was populated
with data representing ﬁctitious treatments for the purpose of
testing the model and identifying parameters with the greatest
inﬂuence/effect on results. Three possible values were considered
for all treatment-dependent input parameters (e.g., mean times
to disease-related events or AEs, unit cost): low, medium, and
high. These values covered the range of efﬁcacy and tolerability
estimates from a mixed treatment comparison previously pub-
lished, and the range of current unit costs for antidepressants in
the United Kingdom [17]. Other input data sources are presented
in Table 1.
Cost and QALYs were simulated initially for a “base-case”
treatment strategy, represented in Figure 1, with medium efﬁ-
cacy, medium tolerability, and medium price in ﬁrst line. Treat-
ment characteristics in second and third lines depend on the
reasons for switch: Switch for lack of efﬁcacy: The patient switches to a more
effective treatment with more side effects. Switch for AEs: The patient switches to a less effective treat-
ment with fewer side effects.
From the fourth line, a medium treatment is assumed to be
prescribed, independent of previously received treatments.
To identify the key drivers of costs and effectiveness (QALYs),
sensitivity analyses were implemented. For each treatment-
speciﬁc parameter, two strategies with low and high values were
compared, with all other parameters at medium value. For non–
treatment-speciﬁc parameters, each value was successively sub-
stituted by lower and high estimates and results were compared
with the base case, for the medium strategy represented in
Figure 1. Finally, incremental cost-effectiveness ratios were
estimated for a comparison between two strategies: an existing
strategy, as represented in Figure 1, and a new strategy with a
drug with high effectiveness and high price in ﬁrst line. The effect
of the time horizon on the incremental cost-effectiveness ratio
was examined.
The history of a cohort of 1000 patients was simulated over 5
years. The same cohort was used for all analyses to ensure
Table 1 – Model parameters and input values.
Parameter Source Dependent
on
Base-case value Scenarios
Age (y) (percentages by age
category)
Adult psychiatric
morbidity in
England, 2007
18–34 35–44 45–54 55–64 65–74
Male 23% 22% 24% 20% 11%
Female 24% 18% 26% 16% 16%
–
Sex (percentage of women in the
MDD population)
Adult psychiatric
morbidity in
England, 2007
63% of females –
General mortality UK Ofﬁce of
National
Statistics
Sex, age Gompertz law
Men α ¼ 0.0000370 and β ¼ 0.0925091
Women α ¼ 0.0000144, and β ¼ 0.0999890
Work status (percentage of
workers in the MDD
population)
Borghi and Guest
[25]
52.2% of workers –
Number of previous episodes Mueller et al. [26] 0: 37%/1: 23%/2: 13%/3 and þ: 27% –
Residual symptoms (percentage
of patients having residual
symptoms)
Assumption 20% –
Treatment impact on prominent
symptoms
Assumption Treatment HR ¼ 1 for all treatments HR ¼ 0.5
HR ¼ 1
Probabilities of sexual
dysfunction at remission
Cochrane review
[24]
Treatment High rate: 9% Treatment A: low rate
Medium rate: 6.5% Treatment B: high rate
Low rate: 4%
Duration of sexual dysfunction Assumption Treatment High duration: 60 d Treatment A: short
durationMedium duration: 45 d
Treatment B: long
duration
Low duration: 30 d
Probabilities of AEs over 8 wk:
nausea
Cochrane review
[24]
Treatment High rate: 26% Treatment A: low rate
Medium rate: 19% Treatment B: high rate
Low rate: 12%
Probabilities of AEs over 8 wk:
headache
Cochrane review
[24]
Treatment High rate: 20% Treatment A: low rate
Medium rate: 15.5% Treatment B: high rate
Low rate: 11%
Probabilities of AEs over 8 wk:
diarrhea
Cochrane review
[24]
Treatment High rate: 18% Treatment A: low rate
Medium rate: 12% Treatment B: high rate
Low rate 6%
Probabilities of AEs over 8 wk:
insomnia
Cochrane review
[24]
Treatment High rate: 14% Treatment A: low rate
Medium rate: 10.5% Treatment B: high rate
Low rate: 7%
Probabilities of AEs over 8 wk:
Other AEs
Cochrane review
[24]
Treatment High rate: 37% Treatment A: low rate
Medium rate: 29% Treatment B: high rate
Low rate: 21%
Assumption 5%
Continued on next page
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Proportion of major sexual
dysfunction
Proportion of major
sexual dysfunction
¼ 0%
Proportion of major
sexual dysfunction
¼ 10%
Proportion of major nausea Assumption 1% Proportion of major
nausea ¼ 0%
Proportion of major
nausea ¼ 2%
Proportion of major headache Assumption 2% Proportion of major
headache ¼ 0%
Proportion of major
headache ¼ 4%
Proportion of major diarrhea Assumption 1% Proportion of major
diarrhea ¼ 0%
Proportion of major
diarrhea ¼ 2%
Proportion of major insomnia Assumption 3% Proportion of major
insomnia ¼ 0%
Proportion of major
insomnia ¼ 6%
Proportion of other major AEs Assumption 3% Proportion of other major
AEs ¼ 0%
Proportion of other major
AEs ¼ 6%
Partial response rate at 4 wk Assumption Treatment High rate: 70% Treatment A: high rate
Medium rate: 55% Treatment B: low rate
Low rate: 40%
Clinical remission rate 4 wk after
partial response
Assumption Treatment High rate: 50% Treatment A: high rate
Medium rate: 40% Treatment B: low rate
Low rate: 30%
Normal functioning after 2 wk
clinical remission
Assumption Treatment High rate: 80% Treatment A: high rate
Medium rate: 60% Treatment B: low rate
Low rate: 40%
Relapse rate at 6 mo Gilchrist and
Gunn [27]
Treatment High rate: 46% Treatment A: low rate
Medium rate: 20% Treatment B: high rate
Low rate: 10%
Time to recurrence Mueller et al. [26] Number of
previous
episodes
Weibull law Time to recurrence
reduced by 20%(m ¼ 7.33 and s ¼ 1.33)
Time to recurrence
increased by 20%
Treatment duration GPRD analysis Line of
treatment
First line: 201 d Treatment duration
reduced by 20%Second line: 157d
Treatment duration
increased by 20%
Third line: 161 d
Fourth line: 143 d
Time to suicide attempt GPRD analyses Rate per 100,000 at 1 mo: Time to suicide attempt
reduced by 20%Depression: 49.38
Continued on next page
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Table 1 – continued
Parameter Source Dependent
on
Base-case value Scenarios
Time to suicide attempt
increased by 20%
Full remission and recovery: 10.35
Risk of dying of suicide attempts Khan et al. [28] 10% Risk of dying ¼ 5%
Risk of dying ¼ 15%
Variation of time to side effect
after treatment adjustment for
AE
Assumption No variation Risk of AE decreased by
20%
Variation of time to side effect
after treatment adjustment or
addition
Assumption No variation Risk of AE after
adjustment and after
addition increased by
20%
Relative effectiveness after
addition
Assumption No variation Time to events decreased
by 20%
Relative effectiveness after
treatment adjustment for AE
Assumption No variation Time to events increased
by 20%
Relative effectiveness after
treatment adjustment or
addition for lack of efﬁcacy
Assumption No variation Time to events increased
by 20%
Relative effectiveness ﬁrst line
vs. second line
Assumption No variation Time to events for second
line increased by 20%
Treatment pathway after no
partial response or no
remission at 4 wk
Assumption Switch: 7.5% Switch: 25%
Treatment adjustment: 37.5% Treatment adjustment:
25%Addition: 5%
Addition: 25%No change: 50%
No change: 25%
Treatment pathway after no
partial response at 4 wk
Assumption Switch: 7.5% Switch: 25%
Treatment adjustment: 37.5%
Treatment adjustment:
25%
Addition: 5%
Addition: 25%
No change: 50%
No change: 25%
Treatment pathway after no
remission at 4 wk after partial
response
Assumption Switch: 7.5% Switch: 25%
Treatment adjustment: 37.5% Treatment adjustment:
25%Addition: 5%
Addition: 25%No change: 50%
No change: 25%
Utility of depression Sapin et al. [14] 0.33 (moderate depression, baseline) Utility ¼ 0.15 (severe
depression baseline)
Utility ¼ 0.44 (moderate
depression, 8 wk)
Utility of partial response Sapin et al. [14] 0.72
Continued on next page
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Utility ¼ 0.58
(nonresponder, 8 wk)
Utility ¼ 0.79 (clinical
remission)
Utility of clinical remission Sapin et al. [14] 0.79 Utility ¼ 0.72 (partial
response)
Utility ¼ 0.86 (full
remission)
Utility of full remission Assumed
identical to
recovery
0.86 None
Utility of recovery Sapin et al. [14] 0.86 None
General practitioner visits/
psychiatrist visits
NICE guideline
[15]
Depression
status
Acute period: one GP/specialist
visit every 2 wk
Visit multiplied by 2 in
the acute phase
Maintenance period: one GP/specialist
visit every 2 mo
Visit divided by 2 in the
acute phase
75% of GP/25% of specialist Visit multiplied by 2 in
the maintenance phase
Visit divided by 2 in the
maintenance phase
Mean number of sick leave days Borghi and Guest
[25]
Depression
status
2.67 d per month Mean number reduced
20%0 in recovery
Mean number increased
20%
Mean number of hospitalization
days
Borghi and Guest
[25]
Depression
status
0.225 d per month Mean number reduced
20%0 in recovery
Mean number increased
20%
Additional GP visit for treatment
adjustment, addition or switch
Clinical practice 1 additional GP visit Additional GP visits ¼ 2
Additional GP visit for treatment
adjustment
Clinical practice 1 additional GP visit Additional GP visits ¼ 2
Additional GP visit for addition Clinical practice 1 additional GP visit Additional GP visits ¼ 2
Additional GP visit for switch Clinical practice 1 additional GP visit Additional GP visits ¼ 2
Discount rate NICE guideline
[15]
3.5% for cost and outcomes Discount of outcomes
¼ 0% and discount of
cost ¼ 0%
Discount of outcomes
¼ 8% and discount of
cost ¼ 8%
AE, adverse effects; GPRD, General Practice Research Database; HR, hazard ratio; MDD, major depressive disorder; NICE, National Institute for Health and Care Excellence.
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 8 3 – 1 9 5192comparability, and the baseline demographic characteristics
were representative of patients with MDD in the United Kingdom.
Inputs reﬂecting the UK setting were chosen because of the good
availability of data in the United Kingdom and because this
would allow comparisons with results of previous models. Costs
were estimated from the perspective of the National Health
Service (NHS) and Personal Social Services (NHS&PSS) and from
the societal perspective. The human capital approach was used
for estimating the costs of lost productivity, and presenteeism
was ignored. Costs and QALYs after the ﬁrst year were discounted
to present value at an annual rate of 3.5% per annum.
All input data and associated data sources are shown in
Table 1.Results
Disease Status
In the ﬁrst year, an average patient treated with the “medium stra-
tegy” spent 145 days in depression (deﬁned as not in full remission
or recovery), 167 days in full remission, and 52 days in recovery
(Fig. 3). The number of days in recovery increased to 214 in the
third year and then decreased each year because of mortality and
discounting.Cost Estimates
The total cost for the medium strategy over 5 years was £3,892
(standard error [SE] £60) per patient from the NHS&PSS perspec-
tive and £11,885 (SE £325) from the societal perspective. Total
costs per year decreased substantially over the ﬁrst 2 years, as theTable 2 – Results of comparisons between different treat
Comparison QALYs (A  B)
Year 1 Year 5 Tot
Effectiveness: A, high effectiveness B, low
effectiveness
0.060 0.001 0.0
Partial response rate at 4 wk: A, high rate
B, low rate
0.040 0.006 0.0
Clinical remission rate 4 wk after partial
response: A, high rate B, low rate
0.008 0.002 0.0
Normal functioning after 2 wk in clinical
remission: A, high rate B, low rate
0.003 0.001 0.0
Relapse rate: A, low rate B, high rate 0.014 0.004 0.0
Probabilities of AEs: A, low rate of all AEs
B, high rate of all AEs
0.005 0.002 0.0
Probabilities nausea: A, low rate B, high
rate
0.002 0.001 0.0
Probabilities of headache: A, low rate B,
high rate
0.001 0.002 0.0
Probabilities of diarrhea: A, low rate B,
high rate
0.005 0.003 0.0
Probabilities of insomnia: A, low rate B,
high rate
0.003 0.001 0.0
Probabilities of other AEs: A, low rate B,
high rate
0.001 0.000 0.0
Probabilities of sexual dysfunction A, low
rate B, high rate
0.005 0.003 0.0
Impact of residual symptom A, HR ¼ 1/2
B, HR ¼ 1
0.000 0.001 0.0
AE, adverse event; HR, hazard ratio; QALYs, quality-adjusted life-year; Nnumber of days in depression decreased, and remained stable
afterwards (Fig. 4).
From the NHS&PSS perspective, the costs of physician visits
accounted for 47% of the total costs over 5 years, followed by
hospitalization costs (37%) and antidepressant costs (16%). From
the societal perspective, lost productivity accounted for 68% of
total costs.
Key parameters affecting costs included treatment effective-
ness. The cost of a strategy with high effectiveness in ﬁrst line was
lower than the cost of a strategy with low effectiveness in ﬁrst line
by £602 per patient over 5 years from the NHS&PSS perspective
and £1400 from the societal perspective (Table 2). Non–treatment-
speciﬁc parameters for which the effect on results exceeded twice
the SE included physician visits in the acute phase, parameters
related to the time to recurrence, and discount rate (Fig. 5).
QALY Estimates
The total number of QALYs over 5 years for the medium strategy
was 3.684 (SE 0.014). The number of QALYs by year peaked at
0.785 (SE 0.003) in the second year, because the number of days in
recovery was high during that year, and decreased subsequently
over time because of mortality and discounting.
Differences between treatments in time to partial response,
time to remission, and time to relapse had a signiﬁcant effect on
QALYs (Table 2). The number of QALYs for a strategy with high
effectiveness in ﬁrst line exceeded that of a strategy with low
effectiveness by 0.078 over 5 years. Among different parameters
related to effectiveness, the partial response rate had the greatest
effect. The difference in QALYs between two strategies with
different safety proﬁles in ﬁrst line (low rates for all AEs vs. high
rates for all AEs) was 0.007 over 5 years. However, the effect of
each AE taken individually was lower than the SE. Amongment strategies.
NHS&PSS costs (A  B) Societal costs (A  B)
al Year 1 Year 5 Total Year 1 Year 5 Total
78 363 2 602 780 42 1400
66 105 35 245 192 114 542
21 91 18 238 193 51 815
05 26 2 31 54 110 278
10 171 11 341 348 21 609
07 24 32 74 8 47 336
07 36 16 172 92 99 669
00 13 4 112 35 9 316
08 10 26 27 30 135 343
05 0 32 20 26 5 251
01 11 6 83 11 68 88
08 10 26 27 30 135 343
01 3 1 71 17 130 53
HS&PSS, National Health Service and Personal Social Services.
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are the key drivers of QALYs. The discount rate, however, would
have less effect on incremental costs and QALYs, as well as the
incremental cost-effectiveness ratio, because incremental costs
and QALYs decrease over time.
Incremental Cost-Effectiveness
When comparing two strategies with high effectiveness and high
price versus low effectiveness and low price in ﬁrst line, the ﬁrst
strategy was estimated to be less expensive by £243 from the
NHS&PSS perspective for a gain of 0.078 QALYs over 5 years. The
SE around incremental costs was £75, that is, 30% of the mean,
and the SE around incremental QALYs was 0.010, or 13% of the
mean. Reducing the time horizon to 3 years reduced incremental
costs by 33%.
Assuming a cost-effectiveness threshold of £30,000, the
parameters with the most effect on net monetary beneﬁt were
treatment effectiveness and especially treatment partial response
rate and treatment relapse rate (see Figure in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.11.012).Discussion
This article proposes an innovative core disease model for MDD
aiming to simulate patient pathways in a ﬂexible and realistic
manner, and to facilitate the economic evaluation of different
treatment strategies in MDD, taking into account health technol-
ogy assessment requirements from different countries where
models are used.
This model was tested for ﬁctitious treatment strategies,
based on data from the literature and UK unit costs. The analyses
showed that costs were highest in the ﬁrst year and remained
signiﬁcant in subsequent years. The largest cost components
were productivity costs from the societal perspective and costs of
physician visits and hospitalizations from the NHS&PSS perspec-
tive. Costs were strongly dependent on treatment effectiveness,
as well as frequency of physician visits and parameters related to
recurrence. The parameters driving estimates of QALYs included
treatment effectiveness, health state utilities, and discount rates.
A time horizon shorter than 3 years was not long enough to
capture the full incremental costs and incremental QALYs
between two strategies with different effectiveness in ﬁrst line.
This stems from the assumption that patients who achieved
recovery with a given treatment would receive it again as ﬁrst-
line treatment in case of recurrence.
Cost estimates appeared plausible in the light of previously
published studies for the United Kingdom. Previous economic
models for the United Kingdom estimated the costs of MDD from
the NHS&PSS perspective at £486 over 12 months for selective
serotonin reuptake inhibitors in primary care, £516 to £585 for
serotonin–norepinephrine reuptake inhibitors in primary care
and £1622 to £1667 for serotonin–norepinephrine reuptake inhib-
itors in secondary care over 12 months [18], £376 to £465 over 6
months for escitalopram [19], and £1459 to £2177 over 14 months
[20]. Thus, our base-case estimate of £1486 over 12 months for a
strategy with “medium treatment” in ﬁrst line lies in the range of
previous model estimates. In addition, the cost structure is also
consistent with previous studies. A review of productivity costs
found that they accounted for approximately 60% of total costs in
MDD [17], which is comparable to the proportion of 68% esti-
mated here.
According to new International Society for Pharmacoeconom-
ics and Outcomes Research guidelines, the validation of the
model involves ﬁve steps: face validity, veriﬁcation, cross validity,
external validation, and predictive validation. As mentionedabove, we performed the ﬁrst three of these: the face validity
with expert board meetings to validate the structure and assump-
tions on the model, the veriﬁcation in performing quality control
of the programming, and the cross validation with comparisons
with previously published UK models.
Compared with previous models, the proposed model has
several advantages, such as a longer time horizon. As noted
above, using a shorter time horizon led to a reduction in
incremental costs and incremental QALYs. In addition, this
model considers a state of partial response before remission,
whereas existing models had a response state followed by
remission, or a remission state only. Data on clinical response
are more widely available from clinical trials, but we believe that
the partial response state provides a more realistic representa-
tion of clinical practice: the lack of partial response at 4 weeks
may require a switch, whereas patients with signiﬁcant sympto-
matic improvement who did not reach the usual response criteria
are unlikely to switch (unless they also experience AEs). This
state is important, as shown by the fact that the utility in partial
response was among the parameters with the greatest effect on
the number of QALYs. Furthermore, the time to partial response
was the treatment-related parameter with the largest effect on
incremental QALYs. Another important characteristic of this
model is the level of detail related to AEs. We found that one
AE had a relatively small effect on costs and QALYs, but changing
the probability of all AEs had a signiﬁcant effect. Depending on
the situation in which the model is applied, this level of detail
may not be required, and it could be sufﬁcient to consider
different types of AEs as one event. Having different types of
events, however, will allow comparisons between treatments
with different effectiveness proﬁles.
Other improvements made in this model appeared to have
little effect on results, for example, the distinction between
“clinical remission” and “full remission,” or adjustments of
efﬁcacy and safety after dose changes or switch. Also, it may be
possible to simplify the model for future adaptation. It should be
noted, however, that these ﬁndings are dependent on the set of
input values used for the reported analyses. For example, the
utilities entered for clinical remission and full remission were
very similar.
The disease states in our model are similar to those in the
conceptual structure of the DES model previously proposed by Haji
Ali Afzali et al. [21], except for the partial response state (a response
state was considered in the previous model). At the time of writing,
no result of that model was published, and so no comparison was
possible. As concerns the model structure, a major difference
concerns AEs, which did not appear explicitly in the previous
structure. In addition, the treatment pathway was not presented;
thus, it was not clear when dose changes or switches would occur,
and how their effect on future events would be captured.
Now that model programs have been made available, the
usefulness of the model will depend on the availability of data to
populate it. The Prospective Epidemiological Research on Func-
tioning Outcomes Related to Major depressive disorder study is a
2-year prospective cohort study currently ongoing in Europe (ct
number: NCT01427439). This study aims at assessing the link
between depression and functioning and includes assessment
tools that will provide relevant data to improve the model
including information on therapeutic management of depressed
patients, resource utilization, and utilities. It will also be possible
to estimate the multiplicative factors applied to times to events
in case of dose adjustment (reduction or increase), addition of an
antipsychotic, or switching to the next treatment line, as well as
the correlations between attributes. The ﬁrst communication of
baseline results is planned in 2014. Although utility data already
exist, the only source of EuroQol ﬁve-dimensional questionnaire
utilities by MDD state is the article of Sapin et al. [14], which is
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estimate new utilities, matching exactly the health states of the
model, from the observational study. Adaptations of the model
for different countries will require collecting local unit costs, as
well as collecting local resource utilization data or adapting
estimates from other countries with local clinical experts. Treat-
ment patterns and probabilities of dose titration, switching, and
discontinuation should also be revised in model adaptations.
Administrative or medical records databases may provide useful
data for this purpose; however, obtaining probabilities of switch
or discontinuation (AE or lack of efﬁcacy) will be challenging. A
possibility would be to adjust the probabilities estimated from
the observational study according to the difference in overall
probabilities of switch and discontinuation. When the model is to
be adapted for new products, we would recommend conducting
network meta-analyses to obtain estimates of efﬁcacy and safety
parameters that are comparable to those for existing products,
and take into consideration all the evidence available for each
product. As explained below, however, this may limit the choice
of statistical distributions for simulating times to events.
As concerns limitations of this model, comorbidities of MDD
were not considered. There is much comorbidity associated with
MDD. Some belong to the central nervous system therapeutic
area, for example, insomnia or anxiety, but other diseases such
as diabetes or cancer could also be considered as comorbidities of
MDD. It would not be feasible to consider all of them in one
model. It may be required, however, to incorporate comorbidities
when treatment strategies targeting patients with speciﬁc comor-
bidities are developed. The most important comorbidities to
consider would be those interacting with the efﬁcacy or safety
of treatments. Another limitation is that no effect of residual
symptoms on relapse or recurrence was integrated, although
several publications report that patients with residual symptoms
are more likely to have a relapse or recurrence [22,23]. Although
this would be possible with our model structure, this relationship
was not incorporated in the model, because the data found in the
literature were not sufﬁciently detailed for that purpose.
Other improvements may also be considered in future ver-
sions. A differentiation between levels of severity of depression,
with different health state utilities, would be appropriate, in
particular because the severity of depression following a relapse
may differ from the initial severity. The possibility to reach
normal functioning before clinical remission could also be taken
into account. AEs of antipsychotics could be added, especially
weight gain. Furthermore, the times to AEs were simulated by
using exponential distributions, which imply that the probability
of occurrence of those events was the same every day. Most AEs,
however, have a greater probability of occurrence in the ﬁrst
weeks of treatment. Other distributions should be considered
according to available data. A difﬁculty is that all the evidence
available about existing products should ideally be used; that is,
users should refer to meta-analyses on response rates, relapse
rates, or probabilities of AEs, for example. Meta-analyses, how-
ever, generally provide only one data point for each parameter;
for example, only response rates at 8 weeks are reported in
Cipriani et al. [24]. The only type of distribution that may be ﬁtted
with one data point is the exponential one. A Weibull distribution
would require at least two data points, for example, response
rates at two different time points. In addition, the model would
ideally consider the fact that patients who experienced AEs with
one treatment may be more likely than others to experience the
same events with other treatments. We have no empirical data,
however, to conﬁrm this hypothesis or quantify the effect of
experience of AEs on the risk of future events.
Another limitation of our model is that switches can occur
because of AEs or because of lack of efﬁcacy. In real life, the
decision to switch is often based on an assessment of symptomimprovement relative to AEs; that is, AEs may be better accepted
and less likely to lead to switch if symptoms are much improved.
Another important addition for some countries, such as the
United Kingdom or The Netherlands, would be psychotherapies.
There is wide variability among psychotherapeutic approaches.
In the current model, short psychotherapies, such as cognitive-
behavioral therapies, can be implemented in the model as a
pharmacological treatment or as an addition to conventional
antidepressants. The methods for incorporating psychotherapies
in the model, however, could be improved, and this will be one of
the priorities for future developments of the model.
Another possible improvement could be to include hospital-
ization as a treatment option. In the current version, we consid-
ered the costs of hospitalization, but not their effect on disease
status. An average treatment was assumed in our analyses for
resistant patients (with at least three previous lines of treatment).
These patients, however, are often hospitalized. Taking into
consideration other medications prescribed in combination with
antidepressants, without restriction to antipsychotics, for exam-
ple, thyroid hormones or lithium, would not necessitate any
change in the model structure.
The model running time was 12 minutes for two strategies
over 5 years, with 1000 patients. This number of patients
provided SEs representing 40% of incremental costs and 10% of
incremental QALYs when comparing two strategies with differ-
ent effectiveness and price in ﬁrst line. This variability may
reﬂect the heterogeneity in patient pathways in reality and is
not an indicator of the quality of the model. It has implications,
however, for the number of patients to be deﬁned in such
analyses based on this model. For example, to detect a difference
of 0.078 in QALYs (as observed in our analyses of incremental
effectiveness) with an SE of 5% of that value, the number of
patients would have to be about 6000. The running time will also
be a hurdle at the time of conducting probabilistic sensitivity
analysis to assess second-order uncertainty. We are currently
considering ways to improve the running time, such as reprog-
ramming the model by using alternative software.
To conclude, we have developed a model that provides the
potential to assess the cost-effectiveness of alternative treatment
strategies in MDD with more accuracy than do existing models. It
is a ﬂexible model and can be adapted for the evaluation of a
wide range of different treatment strategies. This is not intended
to be a deﬁnitive model, and we expect that it will be improved
over time, but we believe that it can already be useful in its
current version.
By choosing to make it open-source and freely available on
the Internet, we hope to foster the research community to
develop, implement, and share new data and functions to
populate, enhance, and validate the model.Acknowledgments
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